| 马万省,刘文昭,齐贞光,牟俊宇,李好友.益心康泰胶囊联合硫氮唑酮对不稳定型心绞痛患者心功能及血清ET-1、Hcy、cTnT水平的影响[J].,2021,(17):3392-3395 |
| 益心康泰胶囊联合硫氮唑酮对不稳定型心绞痛患者心功能及血清ET-1、Hcy、cTnT水平的影响 |
| Effects of Yixin Kangtai Capsule Combined with Azolidone on Cardiac Function and Serum Levels of ET-1, Hcy and cTnT in Patients with Unstable Angina Pectoris |
| 投稿时间：2021-03-08 修订日期：2021-03-31 |
| DOI：10.13241/j.cnki.pmb.2021.17.041 |
| 中文关键词: 益心康泰胶囊 硫氮唑酮 不稳定型心绞痛 心功能 ET-1 Hcy cTnT |
| 英文关键词: Yixin Kangtai capsule Azolidone Unstable angina pectoris Cardiac function ET-1 Hcy cTnT |
| 基金项目:山东省卫生厅科研计划项目（2013WS2761） |
|
| 摘要点击次数: 707 |
| 全文下载次数: 401 |
| 中文摘要: |
| 摘要 目的：探讨益心康泰胶囊联合硫氮唑酮对不稳定型心绞痛（UAP）患者心功能及血清ET-1、Hcy、cTnT水平的影响。方法：选择2019年3月到2021年3月期间在我院接受治疗的UAP患者84例，按照随机数字表法分为研究组和对照组各42例，对照组给予阿司匹林、硝酸酯类、?茁-受体阻滞剂及他汀类药物等常规治疗，研究组在其基础上给予益心康泰胶囊联合硫氮唑酮治疗，两组均治疗30 d。对比两组患者的心绞痛疗效、心功能指标、血清学指标、心绞痛发作次数和持续时间、不良反应发生率。结果：研究组临床总有效率高于对照组（P<0.05）。研究组治疗后的QT间期离散度(QTd)、左室舒张末径(LVEDD)、左室收缩末径(LVESD)均低于对照组，而左室射血分数(LVEF)高于对照组 (P<0.05)。治疗后研究组心绞痛发作次数和持续时间均低于对照组（P<0.05）。治疗后研究组患者的血管内皮素1(ET-1)、同型半胱氨酸(Hcy)、心肌肌钙蛋白T(cTnT)水平均低于对照组(P<0.05)。两组不良反应总发生率无明显差异（P>0.05）。结论：益心康泰胶囊联合硫氮唑酮治疗UAP患者疗效较好，能减少患者心绞痛持续时间和发作次数，增强患者的心功能，降低ET-1、Hcy、cTnT水平，且具有较好的安全性，具有一定临床应用价值。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of Yixin Kangtai capsule combined with azolidone on cardiac function and serum levels of ET-1, Hcy and cTnT in patients with unstable angina pectoris (UAP). Methods: A total of 84 patients with UAP treated in our hospital from March 2019 to March 2021 were selected and divided into study group and control group with 42 patients in each group according to random number table method, the control group was given aspirin, nitrates, β-blockers and statins, and the study group was given Yixin Kangtai capsule combined with azolidone on the basis of conventional treatment, both groups were treated for 30 days. The angina efficacy, cardiac function indexes, serological indexes, the frequency and duration of angina attacks, and the incidence of adverse reactions were compared between the two groups. Results: The total effective rate of the study group was higher than that of the control group (P<0.05). After treatment, the QT interval dispersion (QTd), left ventricular end-diastolic diameter (LVEDD) and left ventricular end-systolic diameter (LVESD) in the study group were lower than those in the control group, while the left ventricular ejection fraction (LVEF) was higher than that in the control group(P<0.05). After treatment, the frequency and duration of angina attacks in the study group were lower than those in the control group(P<0.05). After treatment, the levels of endothelin 1(ET-1), homocysteine (Hcy) and cardiac troponin T(cTnT) in the study group were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse events between the two groups(P>0.05). Conclusion: Yixin Kangtai capsule combined with azolidone in the treatment of UAP patients has a good clinical efficacy, can reduce the number and duration of angina attacks in patients, enhance the cardiac function of patients, reduce the levels of ET-1, Hcy and cTnT, and has a good safety, has certain clinical application value. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
